Castor Delivers Strong Finish to 2021, Continues Expansion into US Market

December 16th, 2021 by

HOBOKEN, NJ — December 15, 2021 – Castor, a leading provider of decentralized and hybrid clinical trial solutions, today announced transformative growth with anticipated topline acceleration driven by the company’s momentous US market expansion and focus on life sciences enterprise sales. In 2021, the company reported 125% YoY growth,  more than doubled its workforce, launched New York operations, and powered more than 2,500 studies across the globe.

Life sciences companies, digital health innovators, and researchers trust Castor to power their studies, evidenced by a 98% customer satisfaction rating and an increased customer base of 39% from 2020. Since 2014, Castor has supported over 8,500 studies across 100+ disease indications and reached over 3 million participants across more than 90 countries. 

2021 milestones for Castor include:

“It can be difficult to find fit-for-purpose trial solutions for studies that vary in size, complexity and face different budget constraints. We have partnered with Castor because their solution is easy-to-use and easily scales across varying regulatory environments,” said David Shah,  Manager, Clinical Data Management of Ethicon, a Johnson & Johnson company. “Ultimately, Castor provides us with the ability to set realistic timelines and deliver positive clinical trial experience for both internal, sponsor, and external, participants and sites, users.”

In 2021, Castor continued to deliver on its mission of democratizing global research. During the COVID-19 pandemic, Castor donated its technology and ground-breaking clinical research solutions to more than 300 COVID-19 studies across 40 countries. The company provided free access to its CDMS/eSource and decentralized clinical trial (DCT) solutions for COVID-19 studies to empower researchers, and remove barriers to save lives. 

Castor-supported COVID-19 studies include:

“2021 was a year of transformative growth, and our technology solutions powered the world’s leading COVID-19 projects and  transformative studies  into ‘digital’ cures for patients,” said Derk Arts, CEO and Founder of Castor. “We will continue to innovate to enable researchers to conduct more effective clinical trials while improving the patient experience, to bring new therapies to patients faster.”

Learn more about Castor’s expanding team here. If you’re interested in joining a passionate and collaborative organization bringing clinical trials into the 21st century, Castor is hiring.

About Castor

Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest-rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug-and-play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, eConsent, and real-world data capture. Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security, and reusability of data for researchers worldwide. For more information, visit www.castoredc.com. Follow us on Twitter at @castor.

Contacts

Castor
Dana Perotti
[email protected]

Media
Kimberly Ha
KKH Advisors
[email protected]

Comments closed

Castor named to the 2021 CB Insights Digital Health 150 – List of Most Innovative Digital Health Startups

December 9th, 2021 by

NEW YORK, NY — December 8, 2021 — CB Insights today named Castor, a leading provider of decentralized and hybrid clinical trial solutions, to its third annual Digital Health 150, which showcases the 150 most promising private digital health companies in the world. This year’s Digital Health 150 was unveiled live during CB Insights’ annual Future of Health event. 

The 2021 Digital Health 150 cohort has raised roughly $14.9B in aggregate funding across 522 deals since 2016 and includes startups at various investment stages of development, from early-stage to well-funded unicorns. Companies this year include startups working on data integration & analytics, hybrid remote/ in-person care, digital therapeutics, clinical intelligence, and more.

“This year’s Digital Health 150 is one of our most expansive yet, spotlighting 16 categories including virtual care, clinical trials tech, and workflow automation, as well as adding new categories such as home health tech and computer-aided imaging,” said Brian Lee, SVP of CB Insights’ Intelligence Unit. “Last year’s class has seen more than 20 exits, raised an additional $18.6B in aggregate funding, and announced over 250 partnerships since being recognized, and we’re excited to see the future success of this year’s winners.”

“We’re thrilled that CB Insights has recognized our accomplishments this year, including our efforts supporting all COVID-19 research for the World Health Organization and powering clinical trials for 20+ next-generation digital health companies, alongside fellow finalists MedRhythms, Mahana Therapeutics, and Woebot Health,” said Derk Arts, MD, CEO & Founder, Castor. “The growth and momentum we’re experiencing speak to the value we’re delivering for both pharma, digital health, and researchers across the globe, and are honored to be named to the CB Insights Digital Health 150 ranking this year.”

Through an evidence-based approach, the CB Insights research team selected the Digital Health 150 from a pool of over 11,000 companies, including applicants and nominees. They were chosen based on several factors, including data submitted by the companies, company business models and momentum in the market, and Mosaic scores, CB Insights’ proprietary algorithm that measures the overall health and growth potential of private companies.

Castor offers a leading cloud-based clinical data platform that simplifies the clinical trial process, from recruitment to analysis, for global research. Since 2014, Castor has supported over 8,500 studies across 100+ disease indications and reached over 3 million participants across more than 90 countries. In 2021, Castor closed $45M Series B funding and more than doubled its workforce to 172 employees across 18 countries. Founded on the mission to democratize research across the globe, Castor has been powering ground-breaking COVID-19 research since the start of the pandemic, donating its technology to more than 300 COVID-19 studies across 40 countries.

2021 Digital Health 150 Investment Highlights:

About CB Insights

CB Insights builds software that enables the world’s best companies to discover, understand, and make technology decisions with confidence. By marrying data, expert insights, and work management tools, clients manage their end-to-end technology decision-making process on CB Insights. To learn more, please visit www.cbinsights.com.

About Castor

Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest-rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug-and-play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, eConsent, and real-world data capture. Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security, and reusability of data for researchers worldwide. For more information, visit www.castoredc.com. Follow us on Twitter at @castor.

Contacts

CB Insights
[email protected]

Castor
Kimberly Ha
KKH Advisors
[email protected]

Comments closed

Trialbee and Castor Partner to Democratize Access and Simplify Enrollment to Clinical Trials Globally

September 20th, 2021 by

Industry leaders to increase patient access to clinical research and scale remote enrollment of participants for trial sponsors to promote increased health equity.

MALMO, Sweden and HOBOKEN, N.J., Sept. 21, 2021 – Trialbee, the leading enrollment performance company, and Castor, a leading provider of decentralized and hybrid clinical trial solutions, today announced a strategic partnership to accelerate patient enrollment, optimize patient engagement, and reduce site burden for clinical trials globally.

Castor and Trialbee’s logical integration allows sponsors to meet enrollment timelines with continuous access to all their study data. Together, the fast-growing companies will expedite patient recruitment and streamline clinical trials through advanced data science and streamlined workflows for patient enrollment, data collection, and engagement. The partnership will diversify patient participation and improve equitable health outcomes for global decentralized and hybrid clinical programs. 

“We are excited to partner with Trialbee to improve patient engagement, as well as optimize patient diversity and study inclusivity with real-time insights around patient demographics across all recruitment channels,” said Derk Arts, M.D., Ph.D., CEO & Founder, Castor. “Our partnership provides sponsors a seamless decentralized and hybrid clinical trial solution to manage all their clinical trial touchpoints and expand inclusivity at a global scale.” 

Recruiting and retaining qualified clinical trial participants is increasingly difficult as clinical study designs become more complex. According to industry estimates, the amount of patient eligibility in clinical trials has increased approximately 150% in the last decade. As a result, life sciences companies demand a patient matching and enrollment platform that can help them better manage the patient’s journey into a clinical trial while optimizing enrollment outcomes. With Trialbee and Castor’s proven integrations, clinical trial sponsors can seamlessly manage all clinical trial touchpoints while ensuring data quality every step of the way.

“Over 70 percent of potential clinical trial participants live more than two hours away from a trial site, increasing the need for greater scale and reach in patient awareness for today’s trial designs,” said Matt Walz, Chief Executive Officer at Trialbee. “Through our combined capabilities, clinical trials can deploy an end-to-end solution to simplify the patient journey, including early introductions to clinical trials, enrollment performance analytics, and remote data capture for decentralized clinical trials.”

About Trialbee

Trialbee is the leading global data and technology platform for patient matching and enrollment in clinical trials. Trialbee Hive™ operationalizes real-world data (RWD) and applies data science to match patients globally. Our enrollment platform simplifies the journey for matched patients to qualify and participate in clinical research. Partnering with Sponsors, CROs, and virtual/decentralized sites, and software providers, Trialbee is achieving patient enrollment goals and driving enhancements in diversity in clinical trial populations. We are the smartest way to match and enroll patients for your clinical trial. For more information, visit http://www.trialbee.com or contact us at [email protected]. 

About Castor

Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest-rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug-and-play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, consent, and real-world data capture. Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security, and reusability of data for researchers worldwide. For more information, visit www.castoredc.com.

Contacts

Doug Weatherhead
Castor
[email protected]

Media
Kimberly Ha
KKH Advisors
[email protected]

Rosina Ferrante
Gregory FCA (for Trialbee)
215-344-2113
[email protected]

 

Comments closed

Castor Expands Executive Leadership Team to Scale Clinical Trial Platform Technology

September 14th, 2021 by

HOBOKEN, N.J.– September 15, 2021 — Castor, a leading provider of clinical trial technology to democratize clinical research, announced two executive appointments to accelerate the company’s growth and impact on the industry.  Kimberly Tableman as Chief Clinical Development Officer (CCDO) and Anna Wozniak as Chief Financial & Development Officer (CFDO).

Castor’s new CCDO, Kimberly Tableman, brings more than 23 years of experience in clinical development and technology. Over the past decade, she has focused on applying digital health technologies to reimagine the patient journey. She was most recently CEO at Medicine X, and co-founder at Rabble Health, where she led the development and beta launch of a patient engagement platform to serve Oncology patients. Prior to Medicine X, Kimberly held senior roles at GlaxoSmithKline (GSK), including Head of Patient Engagement and Head of Digital Clinical Trials. She has also worked at Pfizer, and began her career in management consulting at Cap Gemini Ernst & Young. 

 “I am passionately committed to serving diverse patients through products that facilitate a positive research journey and increase accessibility to precision-medicine treatments,” said Tableman. “I am thrilled to be a part of the Castor team and to work alongside peers who are equally dedicated to making patient-centric trials a reality”. 

Anna Wozniak, Castor’s new CFDO, brings more than 14 years of life sciences experience, building and scaling businesses through her focus on strategy, leadership, and driving execution. Anna was previously Executive Vice President Strategy and Development at BC Platforms, a personalized medicine company, driving growth post-Series A through Series C. Before joining BC Platforms, she held various finance and strategy roles at Syngenta. 

“Castor’s technology-first approach to patient-centric research is primed for continued growth given the significant market need for digital transformation,” said Wozniak.  “My experience scaling businesses and accelerating growth has led me to Castor – to deliver on the promise of enabling faster, smarter, clinical research.” 

“Castor has grown tremendously in the past year, and with Anna and Kimberly- we add two strong, strategic leaders to help guide us during this phase of our growth,” said Derk Arts M.D., Ph.D., CEO & Founder, Castor. “I am delighted to welcome Anna and Kimberly to Castor, both highly skilled professionals with decades of experience within these critical corporate operational areas to ensure we can continue to successfully help researchers conduct more effective clinical trials on a global scale while improving the patient experience.”

Learn more about Castor’s expanding leadership team here. And, if you’re interested in joining a passionate and collaborative organization bringing clinical trials into the 21st century, Castor is hiring.

About Castor

Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest-rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug-and-play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, consent, and real-world data capture. Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security, and reusability of data for researchers worldwide. For more information, visit castoredc.com. Follow us on Twitter at @castor.

Contacts

Castor
Dana Perotti
[email protected]

Media
Kimberly Ha
KKH Advisors
[email protected]

Comments closed

Castor EDC has been nominated for the Rising Star award

September 13th, 2016 by
Castor EDC is nominated as a Rising Star in the Deloitte Technology Fast 50 competition.

Castor EDC has been nominated for the Rising Star Award 2016. The Rising Star category is part of the Deloitte Technology Fast 50 and was specifically created for technology companies less than five years old. The nominees will gather on October 13th in Amsterdam to give elevator pitches in hopes of receiving the title of Rising Star 2016 or the Most Disruptive Innovator.

CEO Derk Arts: “We are proud that as a niche player within the medical research community, we have been nominated for such a prestigious award. This feels like appreciation for our recent rapid growth. We cannot wait to show the world what the maximum utilization of research data can mean for the future of healthcare. “

About the company

Castor’s Electronic Data Capture (EDC) accelerates medical research by unlocking the potential of every byte of research data. We enable researchers to capture high-quality, standardized data at the source and make it available for re-use. Castor is the most user-friendly and affordable EDC in the world and is being used by more than 4500 users across 1500 studies.

Martin Wabeke, a partner at Deloitte and program director of the Technology Fast 50: “The Rising Star participant companies show that the Netherlands is a breeding ground for technology, innovation, and potential game changers. These ten jury-nominated companies represent a wide variety of target groups, sectors and revenue models. We expect them to go up high with their pitches and hope to see them grow into future Fast 50 winners. “

About the Rising Star Award

The Deloitte Technology Fast 50 is an annual election of the fifty fastest growing technology companies in the Netherlands. The selection is based on the percentage revenue growth over the past four years (2012-2015). Younger companies can also participate in the Technology Fast 50 programs in the Rising Star category. They are evaluated for sales potential and scalability, rather than growth rates. The Fast 50 nominees were announced on Monday 5th of September. Participants come from both the public and private sector and hail from all technology segments.

Derk Arts pitching for Deloitte Rising Star 2016 explaining why and how Castor is going to accelerate medical research by connecting researchers worldwide and unlocking their full potential.

For more information about Castor EDC, contact Rob Konterman through [email protected] or 020 3374095. For more information about the Rising Star Award, please contact Karen van Schie, Press Officer, Deloitte, 06 82019154 or [email protected]

No comments yet

Castor Appoints Digital Leader Milind Kamkolkar to Board of Directors

November 8th, 2021 by

Industry veteran Milind Kamkolkar joins Castor’s Board of Directors to advance mission of democratizing clinical research by maximizing the impact of clinical data.

HOBOKEN, N.J., November 9, 2021 – Castor, a leading provider of decentralized and hybrid clinical trial solutions, today announced the appointment of industry veteran Milind Kamkolkar to its Board of Directors.

Milind is currently Senior Advisor to Cellarity, a Flagship Pioneering Company, after his tenure as Chief Digital & Data Officer. He brings to Castor more than 20 years of experience in healthcare AI and digital health, from startup, management consulting to Fortune 500 enterprises. As a Board member, Milind will help Castor accelerate its goal of making the world’s research data more accessible, enabling AI-driven clinical trials, and ultimately use actionable data to improve the speed and efficiency of clinical trials.

“The adoption of decentralized clinical trials has seen exponential growth, catalyzing an industry in critical need of modernization,” said Milind. “I was impressed by the leadership, talent and technology at Castor, which complement the hard problems Castor’s platform tackles with technical sophistication. To support the growing clinical research needs of academic centers and life sciences companies, Castor’s technology simplifies the clinical trial process and ‘consumerizes’ new processes for tech-enabled clinical trials. I look forward to contributing my expertise and being a part of Castor’s journey to enable faster, smarter clinical trials.” 

Castor offers a leading cloud-based clinical data platform that simplifies the clinical trial process, from recruitment to analysis, for global research. Castor’s combined Advisory Board & Board of Directors consists of twelve industry leaders that are committed to furthering the company’s mission to make clinical research smarter and faster through technology.

Castor’s Board has been instrumental in fueling Castor’s growth. Since 2014, Castor has supported over 8,500 studies in more than 90 countries. In the last two years, the company more than doubled in size and worked with customers such as the World Health Organization, which used Castor for its Solidarity Trial, landed contracts with over 30 top-tier digital therapeutics companies, and penned enterprise agreements with multiple top 5 pharmaceutical companies.

“We’ve made significant progress in advancing our clinical and technology and practices this year,”  said Derk Arts, PhD, Chief Executive Officer and Founder of Castor. “We are thrilled to have Milind join our Board. His expertise, insights and passion for technology combined with the collective experience of our leadership team and Board, is critical to our ability to operationalize and achieve our vision of democratizing clinical research to maximize the impact of research data for patients worldwide.”

Milind joined Cellarity from Sanofi where he was the first enterprise Chief Data Officer in the pharmaceutical industry. Prior to Sanofi, he was the Head of AI and Data science within the Digital Medicines group at Novartis.

To read more about Castor’s Board of Directors, visit www.castoredc.com/about-us/leadership/.

About Castor

Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest-rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug-and-play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, eConsent, and real-world data capture. Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security, and reusability of data for researchers worldwide. For more information, visit www.castoredc.com.

Contacts

Media
Kimberly Ha
KKH Advisors
[email protected]

Comments closed

Castor is accelerating global medical device research with decentralized clinical trials platform

November 1st, 2021 by

HOBOKEN, N.J. – November 1, 2021 – Castor, a leading provider of decentralized and hybrid clinical trial solutions,  today announced the acceleration of medical device research & development with its decentralized clinical trial platform to power medical device studies globally. By working with over 150 medical device companies, Castor’s DCT platform is increasing the efficiency of launching medical device clinical trials by ensuring regulatory compliance, optimizing the patient experience, and streamlining the real-time collection of research data.

Innovation within the healthcare industry is on the rise, with medical device manufacturers uniquely positioned to make a global impact on the treatment and prevention of diseases. In line with market growth, the medical device landscape is increasingly complex, as global regulatory bodies enforce stricter regulatory standards for medical device trials. 

For manufacturers, new regulations such as MDR-IVDR and the FDA 21st Century Cures Act are changing the path to approval and placing a greater emphasis on data quality, safety, and transparency.  Leveraging Castor’s globally compliant platform, manufacturers can successfully navigate the regulatory landscape and ensure compliance with an easy-to-use, intuitive technology designed to optimize patient engagement and streamline data collection from multiple sources.  

“Castor offers a truly seamless clinical trial experience for investigators and patients,” said Fernando Correia, MD Ph.D., Chief Medical Officer of Sword Health, a digital musculoskeletal (MSK) care provider. “Fast deployment was critical for us. Castor technology was easy to use and the self-service capability allowed us to deploy a study in just a few weeks. When it came time for our next study, we were able to cut the build time in half by reusing previous study builds.”

Castor’s modern interface and integration capabilities enable medical device manufacturers to achieve compliance and focus on patient outcomes, minimizing the burden of managing multiple technologies, vendors, and processes.  Built for single and multi-site medical device clinical trials, Castor’s modular DCT platform can: 

“For us, it’s important that digital technology is accessible and easy-to-use for patients and researchers. That’s why we are so passionate about delivering a complete self-service solution to help medical device manufacturers navigate their trials,” said Derk Arts, Ph.D., M.D., CEO and Founder of Castor. “We are excited by the opportunity to help medical device companies develop high-engagement, patient-friendly and data integrated clinical workflows that streamline the approval process and ultimately deliver the best products to market.” 

The future of clinical trials is here. Learn more about how you can use Castor’s integrated platform in your next medical device trial at castoredc.com. 

About Castor

Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest-rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug-and-play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, consent, and real-world data capture. Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security, and reusability of data for researchers worldwide. For more information, visit www.castoredc.com. Follow us on Twitter at @castor.

Contacts

Media
Kimberly Ha
KKH Advisors
[email protected] 

 

No comments yet

Castor Raises $45M Series B to Modernize the Clinical Trial Process and Maximize the Impact of Research Data on Patient Lives

July 14th, 2021 by

HOBOKEN, N.J. — Castor, a leading provider of clinical trial software, announced today the closing of a $45 million Series B financing round, bringing the company’s total funding to $65 million.

The round, led by Eight Roads Ventures and F-Prime Capital with participation from existing investors Two Sigma Ventures and Inkef Capital, will fuel continued product development with a particular focus on scaling direct-to-patient trials globally.

“Castor was created with the mission to help researchers globally conduct more effective clinical trials while improving the patient experience,” said Derk Arts, M.D., CEO & Founder of Castor. “Prioritizing the patient and site user experience is particularly important today, when COVID-19 has fundamentally changed the nature of clinical trials.”

Most clinical trials today require a long set-up time and are conducted at brick-and-mortar research sites which make trial participation inconvenient for patients and leave researchers in the dark about patient data in-between site visits. As a result, 38.7% of terminated trials being halted due to slow enrollment¹, and the cost to develop a drug has more than doubled in the last decade to $2.7 billion across a 12-year timeline².

Castor offers a modern, self-service clinical research platform, which enables every researcher worldwide to design studies and integrate data from any source in real-time. Patients can enroll themselves in trials, consent and share their data online or via a mobile app, allowing the industry to seamlessly shift to decentralized clinical trials (DCT). These capabilities have been critical during the COVID-19 pandemic as Castor’s customers were able to quickly change their study designs and incorporate increased collection of remote patient data.

Since 2014, Castor has supported over 7,500 studies in more than 90 countries. Over the last 12 months, the company more than doubled in size and it has worked with customers such as the World Health Organization, which used Castor for its Solidarity Trial, and landed contracts with over 20 top-tier digital therapeutics companies and signed its first top 5 pharmaceutical company.

“COVID-19 forced the industry to change and required agility and customer centricity that Castor was uniquely positioned to deliver,” said Michael Treskow, Partner at Eight Roads Ventures.

“We believe that Castor’s visionary approach will significantly improve the quality of clinical research and we are excited to support Derk and the team as they continue to transform the industry on a global scale,” said Alex Pasteur, Partner at F-Prime Capital.

1. Williams RJ, et al. Terminated Trials in the ClinicalTrials.gov Results Database: evaluation of availability of primary outcome data and reasons for termination. PLoS One. 2015;10(5):e0127242.

2. J. DiMasi, et al. Innovation in the pharmaceutical industry: New estimates of R&D costs, Journal of Health Economics, Volume 47, 2016, Pages 20-33

About Eight Roads Ventures

Eight Roads Ventures is a global venture capital firm managing $7bn of assets across offices in the UK, China, India, Japan, and the US. Our 50-year history of investing includes partnerships with over 300 companies such as Alibaba, Appsflyer, BlackDuck, Cazoo, Chewy, Devoted Health, Flywire, Icertis, iPipeline, Kensho, Letgo, Made.com, Neo4j, Nuance, Paidy, Ping Identity, Pony.ai, Toast, Wallapop, WuXi PharmaTech, and Xoom.

About F-Prime Capital

F-Prime Capital is a global venture capital firm investing in healthcare and technology. For the past 50 years, our independent venture capital group has had the privilege of backing great entrepreneurs building groundbreaking companies.

With over $2 billion dollars under management and a global portfolio of more than 200 companies, we champion those dedicated to creating positive change in the world. In healthcare, we focus on therapeutics, medtech and health IT & services in a stage-agnostic fashion. Our healthcare fund has created or co-created 23 companies including Denali, Beam, Innovent, Orchard and Sana and has helped build many others including Blueprint Medicines, Iora Health, PatientPing, Devoted and Ultragenyx. F-Prime portfolio companies have seen more than 28 products and drugs approved by regulatory agencies worldwide. Our team of investors, engineers, doctors and scientists is committed to bringing the insight, domain expertise and relationships required to help our companies make a transformational impact.

F-Prime is headquartered in Cambridge, MA, with offices in London, UK and San Francisco, CA.

Contacts

Media
Kimberly Ha
KKH Advisors
[email protected]

Read more on TechCrunch and Fierce Biotech.

Comments closed

Castor Launches Scalable Decentralized Trial Platform After 383% Commercial Growth

December 17th, 2020 by

Hoboken, New Jersey: December 17, 2020: Castor, a leading provider of clinical trial technology, today announced the launch of its scalable end-to-end decentralized clinical trial (DCT) platform.

With this launch, Castor is meeting the increasing demand in the market for technology that makes trials more patient centric and enables a hybrid approach (in-home or site-based) to trial visits, which has been accelerated by the pandemic. The platform includes modules to support remote enrollment, remote eConsent, native patient-facing apps, a complete EDC, and integrated real-time reporting capabilities. 

On launching the DCT platform, Castor CEO Derk Arts, MD, PhD, said: “Castor has always had a strong focus on patient-centric and technology-enabled trials, as I believe these trials will become the reference standard for the life sciences industry. In the past nine months we focused our product development on creating a platform that makes these trials scalable, as we see an enormous bottleneck in the industry on launching these technologically challenging trials in acceptable timelines.”

The launch comes on the back of a high impact year for Castor, in which they supported the World Health Organization with their landmark Solidarity trials on COVID vaccines and treatments, and supported more than 300 COVID-related trials pro bono. In the second half of the year, commercial growth was 383% compared to the same period in 2019. A major commercial milestone was winning a contract for multiple cross-country eConsent projects with a top 10 pharma company.

Castor will be working closely with the recently launched Decentralized Trials & Research Alliance (DTRA) as one of the founding members to ensure the successful adoption of this technology.

Craig Lipset, DTRA Co-Convener and Castor Advisory Board member, said: “The pandemic has catalyzed the adoption of decentralized clinical trials, and sponsors are increasingly making it clear that there is no going back. While many embraced flexible participation as a necessity for business continuity, they are committing to these approaches to improve patient access, experience, and diversity.”

Castor’s key achievements in 2020 include:

About Castor 

Based in the United States and The Netherlands, Castor is an international health-tech company founded by CEO Derk Arts, MD, PhD. Their cloud-based clinical data platform simplifies the clinical trial process, from recruitment to analysis, for researchers worldwide.

More than 65,000 researchers across 90 countries are using Castor to supercharge their research. Castor’s platform has supported more than 4,000 commercial and academic studies that cover a broad range of therapeutic areas including diabetes, cardiovascular disease, rare diseases, infectious diseases, and oncology. Researchers on the platform generate vast amounts of data from traditional and remote trials, and Castor recently reached milestones of 250,000,000 data points and 2,200,000 enrolled patients. Castor’s goal is to make the world’s research data reusable, enabling AI-driven clinical trials, and ultimately creating a future in which they maximize the impact of data through reuse.

In 2020, Castor raised a $12M Series A from Two Sigma Ventures with participation from Hambrecht Ducera Growth Ventures and existing investor INKEF Capital. Castor previously raised a $6.25M seed round from INKEF Capital in 2018.

LinkedIn: www.linkedin.com/company/ciwit-b-v-
Twitter: www.twitter.com/castor

No comments yet

Back to top